Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruconest for Post-SARS-CoV-2 Neurological Symptoms
NCT04705831Phase 2Completed
- Sponsor
- IMMUNOe Health and Research Centers
- Start
- Jan 2021
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of c1-esterase inhibitor in post acute COVID-19 syndrome (2 arms), sponsored by IMMUNOe Health and Research Centers. Primary endpoints: Behavior Rating Inventory of Executive Function - Adult Version at Week 17, Repeatable Battery for the Assessment of Neuropsychological Status at Week 17 and 15 more. Started Jan 2021; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT04705831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04705831.